title: All-cause and HIV-related mortality rates among HIV-infected patients after initiating highly active antiretroviral therapy: the impact of Aboriginal ethnicity and injection drug use.
abstract: BACKGROUND
  Aboriginals are over-represented in Canada's HIV epidemic and are commonly infected with HIV via injection drug use (IDU); however, little is known about the impact of Aboriginal ethnicity on mortality after starting highly active antiretroviral therapy (HAART). Therefore, we compared mortality rates between Aboriginal and non-Aboriginal HIV patients and between IDU and non-IDU HIV patients after they initiated HAART.
  
  
  METHODS
  We conducted a retrospective cohort study of antiretroviral-naïve patients starting HAART January 1999-June 2005 (baseline), followed until December 2005. We constructed two Cox proportional hazards models, one to estimate all-cause and one to estimate HIV-related mortality hazard ratios (HRs), considering sex, and baseline age, CD4 cell count, HIV RNA level, calendar year, and HAART regimen as potential confounders.
  
  
  RESULTS
  The 548 study patients were followed for 1,889.8 person-years; 194 (35%) were Aboriginal, 255 (46%) were IDUs. We observed 55 deaths; 47% were HIV-related. In multivariable models, Aboriginals experienced higher all-cause (HR = 1.85, 95% CI = 1.05-3.26, p = 0.034) and HIV-related (HR = 3.47, 95% CI = 1.36-8.83, p = 0.009) mortality rates compared to non-Aboriginals; and, compared to patients with other exposures, IDUs experienced higher all-cause (HR = 2.45, 95% CI = 1.31-4.57, p = 0.005) but similar HIV-related (p = 0.27) mortality rates.
  
  
  CONCLUSIONS
  Compared to non-Aboriginals, Aboriginal HIV patients suffer higher all-cause and HIV-related mortality rates after starting HAART. The strongest and most significant predictor of higher all-cause mortality was IDU. Future research should examine reasons for the observed poorer survival of Aboriginal and IDU HIV patients after initiating HAART to develop interventions to improve the prognosis for these vulnerable populations.
authors: Department of Public Health Sciences, School of Public Health, University of Alberta, Edmonton, AB. leah.martin@ualberta.ca
authors: Leah J
authors: LJ
authors: Martin
authors: Stan
authors: S
authors: Houston
authors: Yutaka
authors: Y
authors: Yasui
authors: T Cameron
authors: TC
authors: Wild
authors: L Duncan
authors: LD
authors: Saunders
references: AIDS Res Hum Retroviruses. 2006 Aug;22(8):715-23
references: 16910826
references: AIDS. 2002 May 3;16(7):1051-8
references: 11953472
references: J Viral Hepat. 2004 Nov;11(6):559-62
references: 15500557
references: Ann Intern Med. 2001 May 15;134(10):968-77
references: 11352698
references: Soc Sci Med. 2002 May;54(10):1481-96
references: 12061483
references: J Acquir Immune Defic Syndr. 2000 Apr 1;23(4):360-1
references: 10836763
references: J Acquir Immune Defic Syndr. 2003 Jun 1;33(2):253-8
references: 12794563
references: J Acquir Immune Defic Syndr. 2001 Jan 1;26(1):82-92
references: 11176272
references: Lancet. 2003 Oct 18;362(9392):1267-74
references: 14575971
references: AIDS. 2007 May 31;21(9):1185-97
references: 17502729
references: Ann Intern Med. 2000 Jul 4;133(1):21-30
references: 10877736
references: Psychol Med. 2008 Mar;38(3):419-31
references: 17976253
references: CMAJ. 1999 Mar 9;160(5):659-65
references: 10102000
references: J Acquir Immune Defic Syndr. 2002 Dec 15;31 Suppl 3:S149-53
references: 12562040
references: J Acquir Immune Defic Syndr. 2007 Dec 15;46(5):607-15
references: 18043315
references: AIDS. 2007 Jan;21 Suppl 1:S5-12
references: 17159588
references: AIDS. 2004 Nov 19;18(17):2333-7
references: 15577550
references: J Clin Epidemiol. 1997 Jan;50(1):105-16
references: 9048695
references: N Engl J Med. 1998 Mar 26;338(13):853-60
references: 9516219
references: Stat Med. 1999 Mar 30;18(6):695-706
references: 10204198
references: Clin Infect Dis. 2005 Jul 1;41 Suppl 1:S7-13
references: 16265618
references: Am J Epidemiol. 2006 Mar 1;163(5):412-20
references: 16394200
references: J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):180-202
references: 19668086
references: J Acquir Immune Defic Syndr. 2001 Jul 1;27(3):251-9
references: 11464144
references: Addiction. 2002 Jan;97(1):39-47
references: 11895269
references: AIDS Res Ther. 2006 May 24;3:14
references: 16723028
references: AIDS Care. 2006 Nov;18(8):968-76
references: 17012087
references: CMAJ. 2005 Jul 19;173(2):160-4
references: 16027432